$12.01
10.91% day before yesterday
Nasdaq, Aug 22, 05:41 pm CET
ISIN
US31773D1019
Symbol
FNCH

Finch Therapeutics Group Inc Stock price

$13.48
+1.09 8.80% 1M
-2.32 14.68% 6M
+2.18 19.29% YTD
+2.22 19.72% 1Y
-59.72 81.58% 3Y
-496.52 97.36% 5Y
-496.52 97.36% 10Y
-496.52 97.36% 20Y
Nasdaq, Closing price Fri, Aug 22 2025
+0.00 0.00%
ISIN
US31773D1019
Symbol
FNCH
Industry

Key metrics

Basic
Market capitalization
$21.7m
Enterprise Value
$5.6m
Net debt
positive
Cash
$16.0m
Shares outstanding
1.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
1.5
Financial Health
Equity Ratio
41.3%
Return on Equity
-326.6%
ROCE
-47.9%
ROIC
-66.7%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-19.5m | $-52.3m
EBIT
$-19.7m | $-33.7m
Net Income
$-14.2m | $-33.8m
Free Cash Flow
$-18.0m
Growth (TTM | estimate)
Revenue
-100.0% | -100.0%
EBITDA
72.2% | -61.1%
EBIT
73.5% | 1.0%
Net Income
89.6% | 54.8%
Free Cash Flow
68.0%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-8.8
FCF per Share
$-11.2
Short interest
2.8%
Employees
1
Rev per Employee
$110.0k
Show more

Is Finch Therapeutics Group Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Finch Therapeutics Group Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Finch Therapeutics Group Inc forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Finch Therapeutics Group Inc forecast:

Buy
86%
Hold
14%

Financial data from Finch Therapeutics Group Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 20 20
50% 50%
-
- Research and Development Expense - -
-
-
-20 -20
72% 72%
-
- Depreciation and Amortization 0.19 0.19
96% 96%
-
EBIT (Operating Income) EBIT -20 -20
74% 74%
-
Net Profit -14 -14
90% 90%
-

In millions USD.

Don't miss a Thing! We will send you all news about Finch Therapeutics Group Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Finch Therapeutics Group Inc Stock News

Positive
Seeking Alpha
4 months ago
ENDI Corp's shares rose significantly, driven by a substantial increase in AUM and a value-unlocking transaction, suggesting further upside potential. Finch Therapeutics awaits a post-trial decision that could significantly impact its share value, with a minimum award level already set. Nam Tai Property secured significant financing and sold a non-core property above appraisal value, indicating...

Company Profile

Finch Therapeutics Group, Inc. engages in the development of microbiome drugs. Its platform includes Human-First Discovery that enables reverse translation from clinical data to engineer the composition of the microbiome based on disease-modifying mechanisms. The company was founded by Mark Smith, Andrew Noh, Tom Borody and Zain Kassam in September 2017 and is headquartered in Somerville, MA.

Head office United States
CEO Matthew Blischak
Employees 1
Founded 2014
Website finchtherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today